Celebrex May Not Pose More Heart Risk Than Others

Celebrex Could Not Pose Extra Coronary heart Threat Than Others

Researchers discovered extra problems, equivalent to bleeding, for the ache relievers ibuprofen and naproxen

WebMD Information from HealthDay

By Robert Preidt

HealthDay Reporter

MONDAY, Nov. 14, 2016 (HealthDay Information) -- Some individuals taking the ache reliever Celebrex could not have a better threat for coronary heart issues than these taking different nonsteroidal anti-inflammatory medicine (NSAIDs), a brand new research says.

Celebrex (celecoxib) is a COX-2 inhibitor. That is the identical class of medication as Vioxx and Bextra, which had been pulled from the market in 2004 and 2005, respectively, as a result of they had been linked to coronary heart issues. Celebrex did not appear to share the identical points, so has remained out there.

And the brand new trial's "main message is that celecoxib is just not riskier for the center than different NSAIDs," mentioned research director Dr. Steven Nissen in a Cleveland Clinic information launch. Nissen is chair of the Division of Cardiovascular Drugs.

Nissen's prior analysis was instrumental in uncovering the cardiovascular dangers related to COX-2 inhibitors.

The brand new research appears to reaffirm Celebrex's security profile. Nonetheless, a number of coronary heart illness specialists aren't satisfied that this research's findings are enough to say that Celebrex is protected for individuals with a excessive threat of coronary heart issues.

This research included greater than 24,000 osteoarthritis or rheumatoid arthritis sufferers worldwide. Their common age was 64. They took one in every of three medicine every day for ache aid: Celebrex, Naprosyn (naproxen) or Motrin (ibuprofen). The sufferers all had pre-existing coronary heart illness or an elevated threat for creating coronary heart illness.

By means of 10 years of follow-up, coronary heart assault, stroke or demise occurred in 2.three p.c of sufferers taking Celebrex, 2.5 p.c of sufferers taking Naprosyn, and a pair of.7 p.c of sufferers taking Motrin, the research confirmed.

The analysis discovered that ulcers or gastrointestinal bleeding was 54 p.c increased within the Motrin group and 41 p.c increased within the Naprosyn group than within the Celebrex group.

Sufferers taking Motrin had a 64 p.c increased threat of worsening kidney perform than these taking Celebrex. Loss of life from any trigger was about 25 p.c increased within the Naprosyn group than within the Celebrex group, however this distinction was very slight, in line with the researchers.

The research was funded by Celebrex maker Pfizer Inc. 4 of the research co-authors work on the drug firm. Pfizer took half within the research design, growth of protocol and assisted with knowledge assortment and maintained the trial database.